GE

310.56

-1.03%↓

RTX

177.19

+0.52%↑

GEV.US

574.19

-0.55%↓

HON

200.03

-6.02%↓

UNP

218.88

+1.11%↑

GE

310.56

-1.03%↓

RTX

177.19

+0.52%↑

GEV.US

574.19

-0.55%↓

HON

200.03

-6.02%↓

UNP

218.88

+1.11%↑

GE

310.56

-1.03%↓

RTX

177.19

+0.52%↑

GEV.US

574.19

-0.55%↓

HON

200.03

-6.02%↓

UNP

218.88

+1.11%↑

GE

310.56

-1.03%↓

RTX

177.19

+0.52%↑

GEV.US

574.19

-0.55%↓

HON

200.03

-6.02%↓

UNP

218.88

+1.11%↑

GE

310.56

-1.03%↓

RTX

177.19

+0.52%↑

GEV.US

574.19

-0.55%↓

HON

200.03

-6.02%↓

UNP

218.88

+1.11%↑

Search

Ocugen Inc

Closed

1.48 -0.67

Overview

Share price change

24h

Current

Min

1.47

Max

1.52

Key metrics

By Trading Economics

Income

611K

-15M

Sales

-108K

1.4M

Profit margin

-1,073.489

Employees

95

EBITDA

724K

-13M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+466.67% upside

Dividends

By Dow Jones

Next Earnings

5 Nov 2025

Market Stats

By TradingEconomics

Market Cap

184M

503M

Previous open

2.15

Previous close

1.48

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Ocugen Inc Chart

Past performance is not a reliable indicator of future results.

Related News

30 Oct 2025, 23:32 UTC

Hot Stocks

Stocks to Watch: Amazon, Reddit, SPS Commerce

30 Oct 2025, 23:02 UTC

Earnings

AIA Group 3Q Value of New Business Grew

30 Oct 2025, 23:45 UTC

Market Talk

Gold Edges Higher Amid Prospects of Continued Central-Bank Demand -- Market Talk

30 Oct 2025, 23:00 UTC

Earnings

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 3rd Update

30 Oct 2025, 22:59 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

30 Oct 2025, 22:59 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Mineral Resources Bear Reckons Lithium Assets May Be Dressed Up For Sale -- Market Talk

30 Oct 2025, 22:56 UTC

Market Talk

Australia Shares Shaping to Pare Recent Losses -- Market Talk

30 Oct 2025, 22:35 UTC

Earnings

AIA Group 3Q Value of New Business Margin Was 58.2%, Up 5.7 Ppt on Year >1299.HK

30 Oct 2025, 22:35 UTC

Earnings

AIA Group 3Q Value of New Business $1.48B Vs. $1.16B>1299.HK

30 Oct 2025, 22:31 UTC

Earnings

Apple Expects Big December Quarter on iPhone Upgrades -- 2nd Update

30 Oct 2025, 22:29 UTC

Earnings

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 2nd Update

30 Oct 2025, 22:27 UTC

Earnings

Minas Buenaventura 3Q EPS 66c >BVN

30 Oct 2025, 22:27 UTC

Earnings

Minas Buenaventura 3Q Rev $431M >BVN

30 Oct 2025, 22:27 UTC

Earnings

Minas Buenaventura 3Q Net $179M >BVN

30 Oct 2025, 22:16 UTC

Market Talk
Earnings

Amazon's Grocery Delivery Business Gains Ground -- Market Talk

30 Oct 2025, 22:14 UTC

Earnings

Review & Preview: A Tech Earnings Storm -- Barrons.com

30 Oct 2025, 22:00 UTC

Earnings
Acquisitions, Mergers, Takeovers

The Day Pharma's Weight-Loss Gold Rush Intensified -- WSJ

30 Oct 2025, 21:39 UTC

Earnings

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30 Oct 2025, 21:26 UTC

Earnings

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30 Oct 2025, 21:14 UTC

Market Talk
Earnings

Apple Sees Record Quarterly Services Revenue -- Market Talk

30 Oct 2025, 21:09 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

30 Oct 2025, 21:09 UTC

Market Talk
Earnings

Amazon Says One-Off Costs Ate Into Operating Income -- Market Talk

30 Oct 2025, 21:04 UTC

Earnings

Apple Expects Big December Quarter on iPhone Upgrades -- Update

30 Oct 2025, 21:03 UTC

Earnings

Eldorado Gold 3Q Gold Sales Were 116,529 Ounces at Avg Realized Gold Price Per Ounce Sold of $3,527 >ELD.T

30 Oct 2025, 21:03 UTC

Earnings

Eldorado Gold 3Q Gold Production Was 115,190 Ounces >ELD.T

30 Oct 2025, 21:00 UTC

Earnings

Eldorado Gold Skouries on Track for 1Q of 2026

30 Oct 2025, 21:00 UTC

Earnings

Eldorado Gold 3Q Adj EPS 41c >EGO

30 Oct 2025, 21:00 UTC

Earnings

Eldorado Gold 3Q Rev $434.7M >EGO

30 Oct 2025, 21:00 UTC

Earnings

Eldorado Gold 3Q Net $56M >EGO

30 Oct 2025, 21:00 UTC

Earnings

Eldorado Gold 3Q EPS 27c >EGO

Peer Comparison

Price change

Ocugen Inc Forecast

Price Target

By TipRanks

466.67% upside

12 Months Forecast

Average 8.5 USD  466.67%

High 15 USD

Low 4 USD

Based on 4 Wall Street analysts offering 12 month price targets forOcugen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

0.6818 / 0.74Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

No Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
help-icon Live chat